Results 201 to 210 of about 832,259 (254)

Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy. [PDF]

Cancer Commun (Lond)
An M, Yan J, Liu B, Liu Q.
europepmc   +1 more source

Microfluidic Nano‐Assembly of Red‐Blood‐Cell (RBC) Lipids and Components for Engineering Extracellular Vesicles

Advanced Healthcare Materials, Volume 15, Issue 41, 6 November 2026.
Engineered red blood cell‐derived extracellular vesicles (eRBCEVs) are synthesized via controlled microfluidic assembly from native RBC lipids, enabling tunable encapsulation of proteins, nucleic acids, nanoparticles, and viral vectors. The platform demonstrates reproducible nanoscale architecture, preserved membrane composition, and functional cargo ...
Chiranth K. Nagaraj, Xilal Y. Rima, Kim T. Nguyen, Courtney Culkins, Nana Boateng, Jacob Doon‐Ralls, Alejandro Bresolin, Xin Huang, Hong Li, Vahedi Amid, Ajeet Pal Singh, Dharti Shantaram, Anastasiia Amari, Mangesh D. Hade, Nicholas R. Merriam, Zachary D. Schultz, Scott Q. Harper, Nizar Y. Saad, Setty M. Magaña, Willa A. Hsueh, Rachel E. Kopec, Blaise R. Kimmel, Andre F. Palmer, Eduardo Reátegui   +23 more
wiley   +1 more source

Rapid CAR screening and circRNA-driven CAR-NK cells for persistent shed-resistant immunotherapy. [PDF]

Signal Transduct Target Ther
Chung JY, Hong J, Yee SM, Lim HW, Lee D, Yoon S, Lee SH, Jung Y, Shin SH, Kim SC, Lee CH, Jang M.   +11 more
europepmc   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

Advanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng, Yuxue Cao, Maria Kavallaris, Taskeen Janjua, Amirali Popat   +4 more
wiley   +1 more source

A Novel MICB-Targeting CAR-NK Cells for the Treatment of Pancreatic Cancer. [PDF]

Int J Mol Sci
Jin W, Wang M, Wang J, Fan J, Fang J, Yang G.   +5 more
europepmc   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, Volume 101, Issue 11, Page 2836-2852, November 2026.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Preclinical and clinical studies on CAR-NK cell therapy: latest update from 2025 ASH Annual Meeting. [PDF]

Exp Hematol Oncol
Luo H, Ding Y, Zhao X.
europepmc   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

Cancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar, Harrison Wildhaber, Rudolf Rohr, Gaëlle Rhyner Agocs, Urban Novak, Alessandra Curioni‐Fontecedro, Vérène Dougoud‐Chauvin   +6 more
wiley   +1 more source

M11‐CAR T cells inhibit murine cytomegalovirus in vitro upon recognition of virion‐ and cell‐associated glycoprotein B

Clinical &Translational Immunology, Volume 15, Issue 11, 2026.
Abstract Objectives Viral infections are predominantly managed with conventional antiviral drugs, which, despite their efficacy, can cause toxicity and promote resistance. Cell‐based immunotherapies offer an alternative, but cytomegaloviruses (CMV) profoundly interfere with MHC class I antigen presentation, thereby impairing conventional virus‐specific
Sabrina Kübel, Christopher Garçon, Hanna Menschikowski, Arne Cordsmeier, Jens‐Christian Albrecht, Friederike Oltmanns, Larissa Bauer, Manuel Hermann, Kristina Holdt, Heinrich Sticht, Marco Thomas, Thomas H Winkler, Brigitte Scholz, Doris Jungnickl, Armin Ensser   +14 more
wiley   +1 more source

Constitutive RLI Armoring Enhances CAR-NK Cell Effector Functions but Causes Lethal Toxicity In Vivo. [PDF]

Int J Mol Sci
Ling Z, Wang Y, Wu G, Lin W, Lu T, Yu G, Wang J.   +6 more
europepmc   +1 more source